Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy
ConclusionsThe aforedescribed observational clinical data relating to a population of Italian inpatients with T2DM suggest that GLP-1ras and SGLT-2is can be considered antidiabetic drugs of choice against COVID-19, and might even prove beneficial in the event of any upcoming pandemic that has life-threatening effects on the pulmonary and cardiovascular systems.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Cardiology | Cardiovascular | COVID-19 | Diabetes | Diabetes Mellitus | Endocrinology | Health Management | Heart | Insulin | Intensive Care | Italy Health | Pandemics | SARS | Sodium | Statistics | Study